AN2 Therapeutics, Inc. (ANTX)
NASDAQ: ANTX · IEX Real-Time Price · USD
8.31
+0.15 (1.84%)
Jul 5, 2022 4:00 PM EDT - Market closed
Income Statement (Annual)
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| Year | 2021 | 2020 |
|---|---|---|
| Selling, General & Admin
|
4.67 | 1.27 |
| Research & Development
|
16.91 | 6.02 |
| Other Operating Expenses
|
0.04 | 6.32 |
| Operating Expenses
|
21.61 | 13.61 |
| Operating Income
|
-21.61 | -13.61 |
| Other Expense / Income
|
-0.07 | -0 |
| Pretax Income
|
-21.54 | -13.6 |
| Net Income
|
-21.54 | -13.6 |
| Preferred Dividends
|
6.52 | 0.98 |
| Net Income Common
|
-28.06 | -14.58 |
| Shares Outstanding (Basic)
|
3 | 3 |
| Shares Outstanding (Diluted)
|
3 | 3 |
| Shares Change
|
2.71% | - |
| EPS (Basic)
|
-10.64 | -5.68 |
| EPS (Diluted)
|
-10.64 | -5.68 |
| Free Cash Flow Per Share
|
-7.76 | -2.09 |
| EBITDA
|
-21.54 | -13.6 |
| EBIT
|
-21.54 | -13.6 |
Source: Financials are provided by
Nasdaq Data Link
and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).